paperKB
coga / coga-kb
Help
Sign in

Chunk #37 — Implications for Clinical Practice

Source
Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
Embedded
yes

Text

as guidelines and labeling increase, so will the likelihood of reimbursement. Certainly, there are many clinical examples that highlight individual instances where using such information has provided knowledge that improved care; however, how testing performs on a larger scale is still uncertain, despite the biological plausibility of the data supporting the labeling and guidelines discussed in this review. Until this knowledge gap is addressed, extensive use will continue to be controversial.